Pricing
  1. JP-listed companies
  2. TRANS GENIC GROUP INC.
  3. Financials
  4. Accounts receivable, net

TRANS GENIC GROUP INC.【JP:2342】

Market cap
¥4.6B
P/E ratio
113.3x
Transgenics Group supports drug development through specialized lab services like genetically modified mice production and pharmaceutical testing, while also providing business consulting and importing various products from electrical equipment to tableware.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndAccounts receivable, net (Million JPY)YoY (%)
Mar 31, 20251,195-11.00%
Mar 31, 20241,343+23.93%
Mar 31, 20231,083+21.18%
Mar 31, 2022894-21.52%
Mar 31, 20211,139+11.56%
Mar 31, 20201,021+47.12%
Mar 31, 2019694+11.01%
Mar 31, 2018625+50.03%
Mar 31, 2017417-14.66%
Mar 31, 2016488+8.19%
Mar 31, 2015451

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)